Grants for Public Housing Authorities

This funding opportunity supports researchers conducting mid-phase clinical trials on natural products, such as botanicals and dietary supplements, to determine optimal dosages and identify patient responses for future studies.

This funding opportunity supports researchers conducting early phase clinical trials on natural products, such as botanicals and dietary supplements, to evaluate their effects on health and inform future studies.

This Notice of Funding Opportunity (NOFO) solicits applications for one or more Data Coordinating Centers (DCCs) to support BRAIN CONNECTS, a networked consortium of Comprehensive Centers and Specialized Projects funded under RFA-NS-22-047, RFA-NS-22-048, and RFA-NS-22-049. The goals of these awards are to develop the research capacity and technical capabilities for comprehensive brain-wide connectivity mapping in mouse, human, and non-human primate (NHP). BRAIN CONNECTS projects will collect and process unprecedented volumes of anatomical data by scaling up cutting-edge acquisition modalities and analysis methods, to demonstrate the feasibility of collecting, reconstructing, analyzing, integrating, disseminating, and interpreting connectivity maps from entire brains. The resulting feasibility data from these awards are expected to inform NIH decisions on program continuation in a potential subsequent five-year funding period for production of brain-wide wiring diagrams. NIH expects to fund one or more BRAIN CONNECTS DCCs, which will collaborate with CONNECTS data generating projects to (1) coordinate activities of the BRAIN CONNECTS Network, (2) develop and harmonize common data processing pipelines, (3) integrate and disseminate data analytic tools and capabilities, (4) establish a unified knowledge base for connectivity data of diverse modalities, and (5) organize and implement outreach and engagement to the wider research community and the general public. Awards will be integrated into the BRAIN CONNECTS Network as a coordinated effort aimed at developing the ability to generate wiring diagrams spanning entire brains across multiple scales and species.

Questions regarding this Funding Opportunity Announcement (FOA) Forecast may be emailed to SCSEP.OGM@dol.gov; however, please note there is limited information that may be shared with the public, as this FOA is currently under development. We encourage prospective applicants and interested parties to use the Grants.gov subscription option to register for future updates provided for this particular FOA.

Sodium-glucose co-transporter-2 inhibitors (SGLT2i) that were developed for the treatment of type 2 diabetes (T2D) have significant protective effects for cardiac and renal diseases for people with and without diabetes. However, SGLT2i are not currently approved for individuals with type 1 diabetes (T1D) and there is an increased risk of diabetic ketoacidosis (DKA) for this population. Despite this concern, these drugs are increasingly being prescribed off-label for people with T1D. Continuous ketone monitoring (CKM) is a rapidly evolving technology that could be utilized clinically to prevent DKA by an early warning of elevations in ketone levels.The purpose of this NOFO is to solicit applications for studies that will develop and test risk mitigation strategies that involve the clinical integration of CKM for the safe use of SGLT2i for people living with T1D so that they may benefit from the cardiac and renal protection and glucose-lowering effects of this drug class. The NOFO will support short-term, clinical trials to gain and disseminate knowledge on safety and glucose control with CKM and SGLT2i use.Possible topics include testing optimal insulin delivery in open and closed loop systems or multiple daily injections and developing clinical protocols to control or ameliorate elevated ketone levels in individuals with T1D who are receiving adjunct therapy with SGLT2i.

The purpose of this notice of funding opportunity (NOFO) is to solicit applications proposing innovative transdisciplinary research that integrates approaches across social/cognitive neuroscience and other social sciences and will lead to a testable conceptual or computational model that provides mechanistic insights into social behavior and its relationships with the onset, trajectory and impact of Substance Use Disorders (SUD) and comorbidities. This NOFO is specifically soliciting applications proposing BESH research, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Application budgets are not limited but need to reflect the actual needs of the proposed project.

This funding opportunity provides support for high-risk clinical trials focused on infectious, immunologic, and allergic diseases, encouraging innovative research that can lead to new treatments and therapies.

The purpose of this notice of funding opportunity (NOFO) is to solicit applications proposing mechanistic transdisciplinary research in animal models that integrates approaches across social/cognitive neuroscience with perspectives from fields with complementary approaches to the study of social behavior, with the goal of developing a testable conceptual or computational model that provides mechanistic insights into social behavior and its relationships with the onset, trajectory and impact of Substance Use Disorders (SUD) and comorbidities. This NOFO is intended to support basic or translational research in non-human animal models, including secondary analysis of data from research in animal models. Applications including studies involving human subjects should submit under one of the companion NOFOs.

The overarching goal of the supported research projects will be to determine neural and cognitive mechanisms that underlie the relationship between social cognition/behavior and the SUD trajectory. The purpose of this notice of funding opportunity (NOFO) is to solicit applications proposing mechanistic, transdisciplinary research on social behavior and its relationships with the onset, trajectory, and impact of Substance Use Disorders (SUDs) and comorbidities. This NOFO is intended to support basic or early translational studies that may, but need not, be considered NIH clinical trials; this may include mechanistic clinical trials, observational studies, or secondary analysis of human data. Clinical trials supported by this funding opportunity are limited to mechanistic clinical trials. A mechanistic clinical trial is designed to understand a biological or behavioral process, the pathophysiology of a disease, biomarkers for a disease or response to treatment, or the mechanism of action of an intervention. It is not designed to test the safety or demonstrate the efficacy/effectiveness of an intervention. This NOFO is not intended to support studies designed to test the safety or demonstrate the efficacy of an intervention. Application budgets are not limited but need to reflect the actual needs of the proposed project.

The "Research Experiences to Enhance Clinician-Scientists' Participation in NIDCDs Research" grant aims to support educational activities and hands-on research experiences that encourage clinicians, particularly those from diverse backgrounds, to pursue research careers in biomedical, behavioral, and clinical sciences, with a focus on areas relevant to the National Institute on Deafness and Other Communication Disorders (NIDCD).

The "NIDCD's Mentoring Networks to Enhance Clinician-Scientists' Participation in Research" grant aims to support educational and mentoring activities that encourage individuals, especially those from diverse backgrounds, to pursue research careers in biomedical, behavioral, and clinical sciences, with a particular focus on improving the recruitment, preparation, and retention of clinician investigators.

This funding opportunity supports researchers exploring the mechanisms and effects of trained immunity in the immune system, particularly its implications for infectious diseases and immune-related conditions.

The purpose of this notice of funding opportunity (NOFO) is to support radiation research at all stages of development for the identification of biomarkers of injury and the development of assays or devices for the purpose of triage, including assessing absorbed dose or predicting health outcomes of acute or delayed injuries resulting from radiation exposure during a public health emergency. This NOFO will support the development of these approaches, with the goal of future regulatory approval. The focus of this NOFO is the development and validation of rapid, reliable, inexpensive, and easy-to-use techniques/assays and devices for use in all segments of the civilian population including geriatric, pediatric, and immune-compromised individuals. Thus, research activities ranging from immediate, early, and delayed changes in radiation-related biomarkers, studies exploring the biokinetics of the proposed biomarker signature, and studies to predict the acute or chronic health outcome in one or more organs are requested. The selection of radiation exposure type, dose level, and dose rates proposed for studies should be relevant to a radiological or nuclear incident and verified by appropriate dosimetry assessments. The ideal radiation signature will be measurable in a non-invasive or minimally invasive way (e.g., finger stick, urine, saliva, or skin scraping as opposed to spinal fluid or complex imaging) that will allow for repeated assays over time, is sensitive to incremental differences in radiation exposure, is specific over a wide range of radiation doses and dose rates and has utility for different qualities of radiation (high and low linear energy transfer).

This funding opportunity supports research projects that explore the basic mechanisms and effects of trained immunity in the innate immune system, targeting a wide range of institutions and researchers interested in immune responses and related diseases.

This cooperative agreement would establish a Center for Home-based Child Care Research to support research about home-based child care (HBCC) in states, territories, This cooperative agreement would establish a Center for Home-based Child Care Research to support research about home-based child care (HBCC) in states, territories, tribes, and/or local community contexts. The purpose of the Center is to provide leadership, build research capacity in the field, and offer support in the development and facilitation of local research to improve understanding of HBCC settings and providers as well as access by the families who seek and utilize HBCC. This research center would promote sound research examining HBCC supply and the factors that support or suppress the availability of HBCC in communities. In addition, this Center would advance the fields understanding of HBCC engagement in public programs and quality improvement efforts. The Centers activities would build research and evaluation capacity in the field and support research in states, territories, and/or tribes that could inform local initiatives designed to sustain and strengthen HBCC.HBCC providers, or individuals and small business owners paid to provide child care in private residences or homes, are an essential segment of the child care landscape. They constitute the largest portion of the child care and early education (CCEE) workforce and serve the vast majority of children birth through school-age who are in regular nonparental care. It is critical for the Administration for Children and Families and for local communities to learn more about HBCC providers, both the individuals providing the care and the characteristics of the programs where they provide child care, in order to inform federal efforts and state, territory, tribal and/or local initiatives to increase access to safe and high-quality child care particularly for families with lower-incomes and working families. The Center would promote sound research examining HBCC and the factors that support or suppress the availability of HBCC in states, territories, and/or tribes. In addition, this Center would advance the fields understanding of HBCC providers engagement in publicly funded programs (e.g., child care subsidies, Head Start) and quality improvement efforts (e.g., Quality Rating and Improvement Systems (QRIS), quality initiatives (QI), and continuous quality improvement (CQI) initiatives). The Centers activities would build research and evaluation capacity in the field and support research in state, territories and/or tribes that could inform local initiatives designed to sustain and strengthen the supply of HBCC. This Center would ideally bring together a team that has experience investigating HBCC, evaluating Child Care and Development Fund (CCDF) program and policies, and assessing the needs and experiences of families with lower-incomes, in tribal communities, and of historically marginalized populations. This Center would be equipped to strengthen the ability of local research partnerships to conduct model research projects that effectively address questions concerning HBCC in local contexts, while contributing to broader understanding in the field about HBCC.

(Reissue PAR-21-058). The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of biomarker measurements within the clinical population of interest to establish the positive and negative predictive values of the candidate biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified.

(Reissue PAR-21-056) The purpose of this Program Announcement (PAR) is to enable analytical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of analytical methods for biomarker measurements, including evaluation of the detection method, its performance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed, and 3) the research and/or clinical need and potential context of use has been identified.

This funding opportunity supports U.S.-based small businesses in the clinical validation of biomarkers for neurological or neuromuscular disorders, promoting inclusivity and collaboration while ensuring rigorous scientific standards for potential diagnostic and therapeutic applications.

This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. A comprehensive understanding of the natural history of a disorder has been identified as a necessary element to facilitate appropriate interventions for infants identified by newborn screening. By defining the sequence and timing of the onset of symptoms and complications of a disorder, a valuable resource will be developed for the field. In addition, for some disorders, specific genotype-phenotype correlations may allow prediction of the clinical course, and for other disorders, identification of modifying genetic, epigenetic, or environmental factors will enhance an understanding of the clinical outcomes for an individual with such a condition. Comprehensive data on natural history will facilitate the field;apos;s ability to: 1) accurately diagnose the disorder; 2) understand the genetic and clinical heterogeneity and phenotypic expression of the disorder; 3) identify underlying mechanisms related to basic defects; 4) potentially prevent, manage, and treat symptoms and complications of the disorder; and 5) provide children and their families with needed support and predictive information about the disorder.

This funding opportunity supports early-stage researchers in cancer control and population sciences to explore innovative ideas that can significantly advance cancer research and improve healthcare delivery.